Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Hutchmed China Ltd (13 HK)
Watchlist
177
Analysis
Industrials
•
Hong Kong
HUTCHMED (China) Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) markets its products worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Akeso Biopharma Inc
•
16 Apr 2024 23:56
[Blue Lotus Healthcare Sector Update]: Bottom-Fishing at the Bottom of the Business Cycle
Liquidity crises in healthcare innovation present buying opportunity;PD-1 exceeds expectations with 20%YoY growth forecast for 2024;Biosimilars...
Blue Lotus Research Institute
Follow
211 Views
Share
bullish
•
BeiGene
•
19 Feb 2024 08:55
BeiGene (6160.HK/BGNE.US/688235.CH) - 2023 Results Preview and Undervaluation Concerns
BeiGene's sluggish share price could be related to geopolitical conflicts/weak market sentiment. But there’s no need for US to sanction China's...
Xinyao (Criss) Wang
Follow
366 Views
Share
bearish
•
Zhejiang Orient Gene Biotech C
•
03 Dec 2023 09:29
China Healthcare Weekly (Dec.1) - Medical Device VBP, Biotech to Breakeven Soon, Orient Gene Biotech
VBP result for intraocular lens/sports medicine consumables is better than expected.There’s a chance to see Chinese Biotech turn loss into profits...
Xinyao (Criss) Wang
Follow
451 Views
Share
bullish
•
iShares MSCI Emerging Markets
•
08 Nov 2023 00:28
MSCI EM Index Reversing 3-Month Downtrend -- Buy. Remain Overweight India, Upgrading Poland & Greece
In our prior EM Strategy (10/2/23) we discussed that, if $EEM is above $37, we were buyers on the pullback. Support held and now EEM displays a...
Vermilion Research
Follow
313 Views
Share
bullish
•
Takeda Pharmaceutical
•
19 Jun 2023 18:32
Takeda: Clinical Development of HUTCHMED’s Fruquintinib Progressing Well
Fruquintinib has demonstrated positive results in a Phase III study while it has also been validated and accepted for regulatory review (MAA) by...
Shifara Samsudeen, ACMA, CGMA
Follow
440 Views
Share
First
Previous
1
2
3
4
5
6
7
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x